Effect of concomitant administration of eicosapentaenoic acid andalendronate on bone changes due to methylprednisolone in rats

One of the main limitations of glucocorticoid therapy is its negative effects on bones.the aim of this study was to determine the effects of concurrent administration ofeicosapentaenoic acid (epa) and alendronate on bone changes induced by glucocorticoidtreatment in rats. thirty six malewistar rats, who were 2.5 months of age, were divided equallyinto six groups and treated with normal saline (controls), 7 mg/kg methylprednisolone (mp),mp with 20 μg/kg alendronate, mp with alendronate and 80 mg/kg epa, mp with alendronateand 160 mg/kg epa, andmpwith alendronate and 320 mg/kg epafor a six-week period.at theend of the experiment, serum and urine samples were collected and the left tibia and femur wereremoved from each animal for histomorphometric studies.there were no significant differences with regards to the levels of serum calcium, phosphorus,creatinine, osteocalcin, carboxy-terminal telopeptide of collagen type i (ctx), alkalinephosphatase, urinary calcium and creatinine, and the phosphorus:creatinine ratios among allgroups. epiphyseal and metaphyseal trabecular widths, and the area of epiphyseal bone and theentire femur in the mp group decreased significantly in comparison to the control group(p<0.001). there were no significant differences in the cortical parameters of the tibial bonebetween these groups. the groups treated with alendronate and alendronate with 80 mg/kg epahad increased epiphyseal trabecular widths compared to the mp group (p<0.001) that werestatistically similar in both groups. the groups treated with alendronate with 80 mg/kg epaandalendronate with 320 mg/kg epahad increased metaphyseal trabecular widths compared to themp group (p<0.001). the groups with alendronate treatment alone and alendronate with 80mg/kg epahad significantly increased bone areas and tissue areas compared to the mp group(p<0.001). in conclusion, concomitant administration of epaand alendronate may improve theknown beneficial effects of alendronate on changes in the bone due tompadministration in rats.